Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Posaconazole

FDA-approved product (suspension, oral), marketed as Noxafil, Noxafil Powdermix Kit, Posaconazole.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Posaconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Candidiasis
  • Coccidioidomycosis
  • Fungal infectious disease
  • Neutropenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC04; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA72.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Posaconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Posaconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)

    NCT00704951 · start 2008-07

    Registered record
    Registry ID
    NCT00704951
    Conditions
    Mycoses
    Interventions
    Posaconazole or alternative fungal treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2008-07
    Completion
    2011-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycoses
    InterventionPosaconazole or alternative fungal treatment
    PhaseNot recorded
    Registry statusWithdrawn

  • Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)

    NCT00686543 · start 2007-12

    Registered record
    Registry ID
    NCT00686543
    Conditions
    Fungal Infection; Acute Myelogenous Leukemia; Neutropenia
    Interventions
    Posaconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-12
    Completion
    2009-04
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Infection; Acute Myelogenous Leukemia; Neutropenia
    InterventionPosaconazole
    PhasePhase 4
    Registry statusCompleted

  • Posaconazole to Treat Invasive Fungal Infections

    NCT00033982 · start 2002-04-11

    Registered record
    Registry ID
    NCT00033982
    Conditions
    Granulomatous Disease, Chronic; Job's Syndrome; Infection
    Interventions
    Posaconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-04-11
    Completion
    2007-02-20
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGranulomatous Disease, Chronic; Job's Syndrome; Infection
    InterventionPosaconazole
    PhasePhase 3
    Registry statusCompleted

  • Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)

    NCT00034632 · start 2001-04

    Registered record
    Registry ID
    NCT00034632
    Conditions
    Mycoses
    Interventions
    Posaconazole oral suspension
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-04
    Completion
    2007-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycoses
    InterventionPosaconazole oral suspension
    PhasePhase 3
    Registry statusCompleted

  • A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

    NCT00002399

    Registered record
    Registry ID
    NCT00002399
    Conditions
    Candidiasis, Oral; HIV Infections
    Interventions
    Posaconazole; Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis, Oral; HIV Infections
    InterventionPosaconazole; Fluconazole
    PhasePhase 2
    Registry statusCompleted